Skip to content

Preliminary clinical study on probiotics Bacteroides fragilis BF839 and Dragon protein in the treatment of senile dementia

Preliminary clinical study on probiotics Bacteroides fragilis BF839 and Dragon protein in the treatment of senile dementia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038146
Enrollment
Unknown
Registered
2020-09-11
Start date
2020-09-14
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

senile dementia

Interventions

experimental group :"Bacteroides fragilis BF839" and "Dragon protein"
control group:Placebo

Sponsors

The Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: >= 50 years old and <= 70 years old. 2. According to clinical symptoms and dementia scale scores, patients who meet the diagnosis of dementia. Patients with Alzheimer's disease (AD), vascular dementia (VaD), mixed dementia, and Parkinson's dementia 3. The patient's eating is not significantly affected by the disease and can eat independently. 4. I/family members can receive follow-up visits and follow-up inspections on time.

Exclusion criteria

Exclusion criteria: 1. Received other clinical trials or new dementia drug treatments within one month. 2. Inability to eat on their own. 3. Patients suffering from tumors, severe heart, liver, and kidney insufficiency, and critically ill diseases. 4. Have obvious protein food allergies.

Design outcomes

Primary

MeasureTime frame
Scale evaluation;

Countries

China

Contacts

Public ContactDeng Yuhong

The Second Affiliated Hospital of Guangzhou Medical University

1376708863@qq.com+86 20-24152843

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026